Ceritinib

Ceritinib

Another Name
LDK378、spexib、Zykadia、塞瑞替尼、赞可达
Indications
Suitable for treating adult patients with metastatic non-small cell lung cancer (NSCLC).
Reg No
06 L 1126/24
Inspection No
1361-24
dosage form:Capsules
Specs:150mg*50Capsules
Indate:24 months
Date：2024-9-1 Views：1113
Drug Info

COMPOSITION:

Each capsule contains Ceritinib………………………….150mg.

INDICATION:

LuciCer is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

DOSAGE AND USE:

750 mg orally once daily. Take LuciCer at least 1 hour before or at least 2 hours after a meal.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciCer during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/ceritinib/

Related News